On February 15, the Centers for Medicare & Medicaid Services (CMS) announced a proposal to cover chimeric antigen receptor (CAR) T-cell therapy for cancer patients who are participating in clinical trials that study treatment effectiveness.
This proposal would require CMS to cover nationwide CAR T-cell therapies "when the treatment is offered in CMS-approved registries or clinical studies in which patients are monitored for 2 or more years following treatment."
“Today’s proposed coverage decision would improve access to this [CAR T-cell] therapy while deepening CMS’s understanding of how patients in Medicare respond to it, so the agency can ensure that it is paying for CAR T-cell therapy for cases in which the benefits outweigh the risks.” --CMS Administrator Seema Verma
A final decision to the proposal is expected May of 2019.
This is incredibly hopeful for myeloma patients as many are on Medicare/Medicaid. We look forward to this coverage approval and it can't come soon enough for patients enrolling on CAR T studies.
about the author
Erika Johnson
Myeloma Crowd Editorial Contributor, Nursing student, and cancer advocate.
Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.